NCNA VS CPIX Stock Comparison

Performance

NCNA
10/100

NCNA returned -59.09% in the last 12 months. Based on SPY's performance of 11.53%, its performance is below average giving it a score of 10 of 100.

CPIX
10/100

CPIX returned -26.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

NCNA
94/100

4 analysts offer 12-month price targets for NCNA. Together, they have an average target of 0, the most optimistic target put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.

CPIX
50/100

1 analysts offer 12-month price targets for CPIX. Together, they have an average target of 0, the most optimistic target put CPIX at 0 within 12-months and the most pessimistic has CPIX at 0.

Sentiment

NCNA
65/100

NCNA had a bullish sentiment score of 65.09% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 1.33 comments, and 2.58 likes per day.

CPIX
67/100

CPIX had a bullish sentiment score of 66.91% across Twitter and StockTwits over the last 12 months. It had an average of 1.69 posts, 0.12 comments, and 0.12 likes per day.

Technicals

NCNA
11/100

NCNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

CPIX
11/100

CPIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

NCNA
10/100

NCNA has missed earnings 7 times in the last 20 quarters.

CPIX
100/100

CPIX has missed earnings 1 times in the last 20 quarters.

Profit

NCNA
10/100

Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CPIX
25/100

Out of the last 20 quarters, CPIX has had 4 profitable quarters and has increased their profits year over year on 4 of them.

Volatility

NCNA
54/100

NCNA has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

CPIX
64/100

CPIX has had a higher than average amount of volatility over the last 12 months giving it a score of 63 of 100.

All score calculations are broken down here to help you make more informed investing decisions

NuCana plc American Depositary Share Summary

Nasdaq / NCNA

Healthcare

Biotechnology

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Cumberland Pharmaceuticals Inc Summary

Nasdaq / CPIX

Healthcare

Drug Manufacturers - Specialty & Generic

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Power up your portfolio